by Clinical Neuropsychologist | Monday, February 24, 2025 | Dementia
Abstract INTRODUCTION The long-term implications of disclosing Alzheimer’s disease (AD) biomarker information to cognitively unimpaired individuals are unknown. METHODS We compared participants who disclosed their elevated amyloid imaging result in a preclinical...
by Clinical Neuropsychologist | Monday, February 24, 2025 | Dementia
Abstract INTRODUCTION Early symptoms in young onset Alzheimer’s disease (YOAD) may be misinterpreted, causing delayed diagnosis. This population-based study aimed to map adverse occupational events preceding YOAD diagnosis as potential prodromal signs. METHODS...
by Clinical Neuropsychologist | Monday, February 24, 2025 | Dementia
Abstract INTRODUCTION We investigated the moderating effects of midlife and late-life cognitive activity (CA) on the relationship between tau pathology and both cognition and cognitive decline. METHODS Eighty-nine non-demented older adults from a Korean cohort...
by Clinical Neuropsychologist | Saturday, February 22, 2025 | Dementia
Abstract INTRODUCTION Isolated REM sleep behavior disorder (iRBD) is a strong prodromal marker of Lewy body diseases (LBDs) – Parkinson’s disease (PD) and dementia with Lewy bodies (DLB). Cholinergic loss is linked to cognitive decline in these conditions, but...
by Clinical Neuropsychologist | Saturday, February 22, 2025 | Dementia
Abstract INTRODUCTION Tau positron emission tomography (PET) is a reliable neuroimaging technique for assessing regional load of tau pathology in the brain, but its routine clinical use is limited by cost and accessibility barriers. METHODS We thoroughly investigated...
